Free Trial
→ ALERT: Drop these 5 stocks before the market opens tomorrow! (From Weiss Ratings) (Ad)tc pixel Free KZR Stock Alerts

Kezar Life Sciences (KZR) Competitors

Kezar Life Sciences logo
$7.34 -0.05 (-0.68%)
Closing price 04:00 PM Eastern
Extended Trading
$7.35 +0.01 (+0.14%)
As of 04:01 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare

KZR vs. MDWD, REPL, ACB, CRBU, and SLGL

Should you be buying Kezar Life Sciences stock or one of its competitors? The main competitors of Kezar Life Sciences include MediWound (MDWD), Replimune Group (REPL), Aurora Cannabis (ACB), Caribou Biosciences (CRBU), and Sol-Gel Technologies (SLGL). These companies are all part of the "pharmaceutical products" industry.

How does Kezar Life Sciences compare to MediWound?

Kezar Life Sciences (NASDAQ:KZR) and MediWound (NASDAQ:MDWD) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, valuation, profitability, media sentiment, risk, dividends, earnings and institutional ownership.

Kezar Life Sciences presently has a consensus target price of $6.00, indicating a potential downside of 18.26%. MediWound has a consensus target price of $35.00, indicating a potential upside of 100.69%. Given MediWound's stronger consensus rating and higher probable upside, analysts clearly believe MediWound is more favorable than Kezar Life Sciences.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Kezar Life Sciences
2 Sell rating(s)
4 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.67
MediWound
1 Sell rating(s)
1 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.25

67.9% of Kezar Life Sciences shares are held by institutional investors. Comparatively, 46.8% of MediWound shares are held by institutional investors. 9.3% of Kezar Life Sciences shares are held by insiders. Comparatively, 9.2% of MediWound shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Kezar Life Sciences has a net margin of 0.00% compared to MediWound's net margin of -140.80%. Kezar Life Sciences' return on equity of -64.42% beat MediWound's return on equity.

Company Net Margins Return on Equity Return on Assets
Kezar Life SciencesN/A -64.42% -54.83%
MediWound -140.80%-65.79%-30.16%

In the previous week, Kezar Life Sciences had 3 more articles in the media than MediWound. MarketBeat recorded 3 mentions for Kezar Life Sciences and 0 mentions for MediWound. Kezar Life Sciences' average media sentiment score of 1.89 beat MediWound's score of 1.02 indicating that Kezar Life Sciences is being referred to more favorably in the media.

Company Overall Sentiment
Kezar Life Sciences Very Positive
MediWound Positive

MediWound has higher revenue and earnings than Kezar Life Sciences. MediWound is trading at a lower price-to-earnings ratio than Kezar Life Sciences, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Kezar Life SciencesN/AN/A-$56.03M-$7.66N/A
MediWound$16.96M13.21-$23.88M-$2.10N/A

Kezar Life Sciences has a beta of 0.4, indicating that its share price is 60% less volatile than the S&P 500. Comparatively, MediWound has a beta of 0.21, indicating that its share price is 79% less volatile than the S&P 500.

Summary

Kezar Life Sciences beats MediWound on 8 of the 15 factors compared between the two stocks.

How does Kezar Life Sciences compare to Replimune Group?

Kezar Life Sciences (NASDAQ:KZR) and Replimune Group (NASDAQ:REPL) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, profitability, media sentiment, institutional ownership, dividends, valuation and risk.

Kezar Life Sciences has a beta of 0.4, indicating that its stock price is 60% less volatile than the S&P 500. Comparatively, Replimune Group has a beta of 0.12, indicating that its stock price is 88% less volatile than the S&P 500.

Kezar Life Sciences currently has a consensus target price of $6.00, indicating a potential downside of 18.26%. Replimune Group has a consensus target price of $4.75, indicating a potential upside of 65.51%. Given Replimune Group's higher probable upside, analysts clearly believe Replimune Group is more favorable than Kezar Life Sciences.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Kezar Life Sciences
2 Sell rating(s)
4 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.67
Replimune Group
4 Sell rating(s)
6 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.60

Kezar Life Sciences is trading at a lower price-to-earnings ratio than Replimune Group, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Kezar Life SciencesN/AN/A-$56.03M-$7.66N/A
Replimune GroupN/AN/A-$247.30M-$3.44N/A

Kezar Life Sciences' return on equity of -64.42% beat Replimune Group's return on equity.

Company Net Margins Return on Equity Return on Assets
Kezar Life SciencesN/A -64.42% -54.83%
Replimune Group N/A -102.69%-72.22%

In the previous week, Replimune Group had 3 more articles in the media than Kezar Life Sciences. MarketBeat recorded 6 mentions for Replimune Group and 3 mentions for Kezar Life Sciences. Kezar Life Sciences' average media sentiment score of 1.89 beat Replimune Group's score of 0.57 indicating that Kezar Life Sciences is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Kezar Life Sciences
2 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Very Positive
Replimune Group
1 Very Positive mention(s)
0 Positive mention(s)
4 Neutral mention(s)
0 Negative mention(s)
1 Very Negative mention(s)
Positive

67.9% of Kezar Life Sciences shares are owned by institutional investors. Comparatively, 92.5% of Replimune Group shares are owned by institutional investors. 9.3% of Kezar Life Sciences shares are owned by insiders. Comparatively, 5.2% of Replimune Group shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Summary

Kezar Life Sciences beats Replimune Group on 7 of the 12 factors compared between the two stocks.

How does Kezar Life Sciences compare to Aurora Cannabis?

Aurora Cannabis (NASDAQ:ACB) and Kezar Life Sciences (NASDAQ:KZR) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, dividends, risk, earnings, profitability, media sentiment and valuation.

Aurora Cannabis has a beta of 0.51, indicating that its share price is 49% less volatile than the S&P 500. Comparatively, Kezar Life Sciences has a beta of 0.4, indicating that its share price is 60% less volatile than the S&P 500.

Aurora Cannabis has higher revenue and earnings than Kezar Life Sciences. Aurora Cannabis is trading at a lower price-to-earnings ratio than Kezar Life Sciences, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Aurora Cannabis$373.12M0.54$1.63M-$1.08N/A
Kezar Life SciencesN/AN/A-$56.03M-$7.66N/A

In the previous week, Kezar Life Sciences had 1 more articles in the media than Aurora Cannabis. MarketBeat recorded 3 mentions for Kezar Life Sciences and 2 mentions for Aurora Cannabis. Kezar Life Sciences' average media sentiment score of 1.89 beat Aurora Cannabis' score of 0.25 indicating that Kezar Life Sciences is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Aurora Cannabis
0 Very Positive mention(s)
1 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Kezar Life Sciences
2 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Very Positive

Kezar Life Sciences has a net margin of 0.00% compared to Aurora Cannabis' net margin of -23.46%. Aurora Cannabis' return on equity of -0.04% beat Kezar Life Sciences' return on equity.

Company Net Margins Return on Equity Return on Assets
Aurora Cannabis-23.46% -0.04% -0.03%
Kezar Life Sciences N/A -64.42%-54.83%

47.6% of Aurora Cannabis shares are owned by institutional investors. Comparatively, 67.9% of Kezar Life Sciences shares are owned by institutional investors. 0.0% of Aurora Cannabis shares are owned by company insiders. Comparatively, 9.3% of Kezar Life Sciences shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Kezar Life Sciences has a consensus target price of $6.00, indicating a potential downside of 18.26%. Given Kezar Life Sciences' higher possible upside, analysts clearly believe Kezar Life Sciences is more favorable than Aurora Cannabis.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Aurora Cannabis
1 Sell rating(s)
1 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00
Kezar Life Sciences
2 Sell rating(s)
4 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.67

Summary

Aurora Cannabis beats Kezar Life Sciences on 8 of the 15 factors compared between the two stocks.

How does Kezar Life Sciences compare to Caribou Biosciences?

Caribou Biosciences (NASDAQ:CRBU) and Kezar Life Sciences (NASDAQ:KZR) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their analyst recommendations, valuation, institutional ownership, risk, profitability, dividends, earnings and media sentiment.

Caribou Biosciences has a beta of 2.27, indicating that its share price is 127% more volatile than the S&P 500. Comparatively, Kezar Life Sciences has a beta of 0.4, indicating that its share price is 60% less volatile than the S&P 500.

Kezar Life Sciences has lower revenue, but higher earnings than Caribou Biosciences. Caribou Biosciences is trading at a lower price-to-earnings ratio than Kezar Life Sciences, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Caribou Biosciences$11.16M17.07-$148.12M-$1.59N/A
Kezar Life SciencesN/AN/A-$56.03M-$7.66N/A

In the previous week, Caribou Biosciences and Caribou Biosciences both had 3 articles in the media. Kezar Life Sciences' average media sentiment score of 1.89 beat Caribou Biosciences' score of 0.00 indicating that Kezar Life Sciences is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Caribou Biosciences
0 Very Positive mention(s)
0 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Kezar Life Sciences
2 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Very Positive

Kezar Life Sciences has a net margin of 0.00% compared to Caribou Biosciences' net margin of -1,327.40%. Kezar Life Sciences' return on equity of -64.42% beat Caribou Biosciences' return on equity.

Company Net Margins Return on Equity Return on Assets
Caribou Biosciences-1,327.40% -78.40% -58.68%
Kezar Life Sciences N/A -64.42%-54.83%

77.5% of Caribou Biosciences shares are owned by institutional investors. Comparatively, 67.9% of Kezar Life Sciences shares are owned by institutional investors. 8.5% of Caribou Biosciences shares are owned by company insiders. Comparatively, 9.3% of Kezar Life Sciences shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Caribou Biosciences presently has a consensus target price of $8.00, indicating a potential upside of 314.51%. Kezar Life Sciences has a consensus target price of $6.00, indicating a potential downside of 18.26%. Given Caribou Biosciences' stronger consensus rating and higher probable upside, equities analysts plainly believe Caribou Biosciences is more favorable than Kezar Life Sciences.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Caribou Biosciences
1 Sell rating(s)
0 Hold rating(s)
2 Buy rating(s)
1 Strong Buy rating(s)
2.75
Kezar Life Sciences
2 Sell rating(s)
4 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.67

Summary

Caribou Biosciences beats Kezar Life Sciences on 8 of the 15 factors compared between the two stocks.

How does Kezar Life Sciences compare to Sol-Gel Technologies?

Kezar Life Sciences (NASDAQ:KZR) and Sol-Gel Technologies (NASDAQ:SLGL) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their valuation, media sentiment, profitability, analyst recommendations, institutional ownership, earnings, dividends and risk.

67.9% of Kezar Life Sciences shares are held by institutional investors. Comparatively, 26.2% of Sol-Gel Technologies shares are held by institutional investors. 9.3% of Kezar Life Sciences shares are held by insiders. Comparatively, 66.5% of Sol-Gel Technologies shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Kezar Life Sciences has a beta of 0.4, indicating that its share price is 60% less volatile than the S&P 500. Comparatively, Sol-Gel Technologies has a beta of 1.16, indicating that its share price is 16% more volatile than the S&P 500.

In the previous week, Kezar Life Sciences had 3 more articles in the media than Sol-Gel Technologies. MarketBeat recorded 3 mentions for Kezar Life Sciences and 0 mentions for Sol-Gel Technologies. Sol-Gel Technologies' average media sentiment score of 1.95 beat Kezar Life Sciences' score of 1.89 indicating that Sol-Gel Technologies is being referred to more favorably in the news media.

Company Overall Sentiment
Kezar Life Sciences Very Positive
Sol-Gel Technologies Very Positive

Kezar Life Sciences has a net margin of 0.00% compared to Sol-Gel Technologies' net margin of -31.60%. Sol-Gel Technologies' return on equity of -24.29% beat Kezar Life Sciences' return on equity.

Company Net Margins Return on Equity Return on Assets
Kezar Life SciencesN/A -64.42% -54.83%
Sol-Gel Technologies -31.60%-24.29%-18.73%

Kezar Life Sciences currently has a consensus target price of $6.00, suggesting a potential downside of 18.26%. Sol-Gel Technologies has a consensus target price of $110.00, suggesting a potential upside of 49.11%. Given Sol-Gel Technologies' stronger consensus rating and higher probable upside, analysts plainly believe Sol-Gel Technologies is more favorable than Kezar Life Sciences.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Kezar Life Sciences
2 Sell rating(s)
4 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.67
Sol-Gel Technologies
0 Sell rating(s)
2 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.33

Sol-Gel Technologies has higher revenue and earnings than Kezar Life Sciences. Sol-Gel Technologies is trading at a lower price-to-earnings ratio than Kezar Life Sciences, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Kezar Life SciencesN/AN/A-$56.03M-$7.66N/A
Sol-Gel Technologies$19.39M10.69-$6.13M-$2.23N/A

Summary

Sol-Gel Technologies beats Kezar Life Sciences on 11 of the 15 factors compared between the two stocks.

Get Kezar Life Sciences News Delivered to You Automatically

Sign up to receive the latest news and ratings for KZR and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding KZR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

KZR vs. The Competition

Export
MetricKezar Life SciencesMED IndustryMedical SectorNASDAQ Exchange
Market Cap$54.11M$3.39B$6.25B$11.87B
Dividend YieldN/A2.20%2.73%5.21%
P/E Ratio-0.9638.8529.0428.47
Price / SalesN/A155.53476.6160.94
Price / CashN/A57.8827.6236.52
Price / Book0.777.039.676.67
Net Income-$56.03M$23.62M$3.55B$332.53M
7 Day Performance0.41%3.67%1.70%2.01%
1 Month Performance-0.81%7.16%5.62%9.20%
1 Year Performance70.70%67.03%34.42%39.59%

Kezar Life Sciences Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
KZR
Kezar Life Sciences
1.4541 of 5 stars		$7.34
-0.7%		$6.00
-18.3%		N/A$54.11MN/AN/A60
MDWD
MediWound
1.704 of 5 stars		$16.56
-0.1%		$31.67
+91.2%		N/A$212.83M$16.96MN/A80
REPL
Replimune Group
3.2051 of 5 stars		$2.57
-4.1%		$4.75
+84.8%		N/A$212.21MN/AN/A210
ACB
Aurora Cannabis
0.7825 of 5 stars		$3.42
-2.6%		N/AN/A$202.16M$246.72MN/A1,130
CRBU
Caribou Biosciences
1.8688 of 5 stars		$2.08
-2.3%		$8.00
+284.6%		N/A$201.01M$11.16MN/A100

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:KZR) was last updated on 5/5/2026 by MarketBeat.com Staff.
From Our Partners
Iran's New Leader Just Said Something That Should Terrify Every American
Iran's Supreme Leader has declared the Strait of Hormuz closed as leverage against the U.S. - and with 40% of ...
American Alternative | Sponsoredtc pixel
Your book attached
Your Download Link (Expiring) If you still haven't downloaded the free Simple Options Trading For Beginners...
Profits Run | Sponsoredtc pixel
My feud with Zohran Mamdani
Emmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...
Stansberry Research | Sponsoredtc pixel
The $1.75T "Backdoor" ticker (NOT Starlink)
When the SpaceX IPO launches, most investors will already be too late. The real opportunity isn't the IPO itse...
Behind the Markets | Sponsoredtc pixel
Sell 99% of Your Stocks, Do THIS Instead…
Millionaire Trader Exposes: "The Single Stock Income Plan" With over 6,000 stocks on the market to choose ...
The Oxford Club | Sponsoredtc pixel
Trade this between 9:30 and 10:45 am EST
The first 75 minutes of the trading day may be the most overlooked window for consistent opportunities.If you ...
Base Camp Trading | Sponsoredtc pixel
Iran War Shock: What I Was Told In That Private Meeting
You’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...
Banyan Hill Publishing | Sponsoredtc pixel
Elon Unveils AI Passive Income Stream for Millions of Americans
During Tesla's last earnings call, Elon Musk outlined a new AI-driven approach he says could generate $30,000-...
InvestorPlace | Sponsoredtc pixel